Jazz Pharmaceuticals plc
JAZZ
$103.58
$5.805.93%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -17.49% | 3.15% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -17.49% | 3.15% | |||
| Cost of Revenue | -17.79% | -18.54% | |||
| Gross Profit | -17.46% | 5.71% | |||
| SG&A Expenses | 28.59% | 22.70% | |||
| Depreciation & Amortization | -2.80% | 0.92% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 7.47% | 8.16% | |||
| Operating Income | -111.38% | -12.16% | |||
| Income Before Tax | -182.85% | -33.57% | |||
| Income Tax Expenses | 69.24% | -298.49% | |||
| Earnings from Continuing Operations | -148.42% | -11.13% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -148.42% | -11.13% | |||
| EBIT | -111.38% | -12.16% | |||
| EBITDA | -65.02% | -6.69% | |||
| EPS Basic | -148.07% | -9.85% | |||
| Normalized Basic EPS | -146.72% | -13.49% | |||
| EPS Diluted | -148.84% | -9.15% | |||
| Normalized Diluted EPS | -147.47% | -12.41% | |||
| Average Basic Shares Outstanding | 0.73% | -1.43% | |||
| Average Diluted Shares Outstanding | -0.85% | -2.65% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||